Major trial tests MS drugs in kids for first time

NCT ID NCT01892722

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to find out which of two existing multiple sclerosis (MS) medications works better and is safer for children and teenagers aged 10-17. About 240 young patients will take either a daily pill (fingolimod) or a weekly injection (interferon beta-1a) for two years, without knowing which one they are getting. After the initial two years, all participants can continue taking the pill medication for an additional five years to help researchers understand the long-term effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AMO Corporation

Tallahassee, Florida, 32312, United States
Childrens Hospital Los Angeles

Los Angeles, California, 90027, United States
Childrens Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104 4399, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Novartis Investigative Site

Parkville, Victoria, 3052, Australia
Novartis Investigative Site

Vienna, 1090, Austria
Novartis Investigative Site

Belo Horizonte, Minas Gerais, 30150 221, Brazil
Novartis Investigative Site

Rio de Janeiro, Rio de Janeiro, 20270-004, Brazil
Novartis Investigative Site

São Paulo, São Paulo, 05403-000, Brazil
Novartis Investigative Site

Goiânia, 74605 020, Brazil
Novartis Investigative Site

Sofia, 1113, Bulgaria
Novartis Investigative Site

Calgary, Alberta, T3B 6A8, Canada
Novartis Investigative Site

Ottawa, Ontario, K1H 8L6, Canada
Novartis Investigative Site

Osijek, 31000, Croatia
Novartis Investigative Site

Tallinn, 10617, Estonia
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Le Kremlin-Bicêtre, 94275, France
Novartis Investigative Site

Marseille, 13885, France
Novartis Investigative Site

Montpellier, 34090, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Göttingen, Lower Saxony, 37075, Germany
Novartis Investigative Site

Dresden, Saxony, 01307, Germany
Novartis Investigative Site

Bochum, 44791, Germany
Novartis Investigative Site

Erlangen, 91054, Germany
Novartis Investigative Site

Bari, BA, 70124, Italy
Novartis Investigative Site

Montichiari, BS, 25018, Italy
Novartis Investigative Site

Catania, CT, 95123, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Cefalù, PA, 90015, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Roma, RM, 00189, Italy
Novartis Investigative Site

Gallarate, VA, 21013, Italy
Novartis Investigative Site

Riga, LV-1004, Latvia
Novartis Investigative Site

Kaunas, LTU, LT 50161, Lithuania
Novartis Investigative Site

Mexico City, D F, 06700, Mexico
Novartis Investigative Site

Distrito Federal, 03310, Mexico
Novartis Investigative Site

Rotterdam, South Holland, 3015 CN, Netherlands
Novartis Investigative Site

Lodz, 93-338, Poland
Novartis Investigative Site

Lublin, 20-093, Poland
Novartis Investigative Site

Poznan, 60-355, Poland
Novartis Investigative Site

Wroclaw, 54-049, Poland
Novartis Investigative Site

Bucharest, 041914, Romania
Novartis Investigative Site

Kazan', 420043, Russia
Novartis Investigative Site

Moscow, 119602, Russia
Novartis Investigative Site

Moscow, 119991, Russia
Novartis Investigative Site

Novosibirsk, 630087, Russia
Novartis Investigative Site

Saint Petersburg, 197110, Russia
Novartis Investigative Site

Belgrade, 11000, Serbia
Novartis Investigative Site

Bratislava, 833 40, Slovakia
Novartis Investigative Site

Seville, Andalusia, 41009, Spain
Novartis Investigative Site

Vigo, Pontevedra, 36212, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Madrid, 28006, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Valencia, 46010, Spain
Novartis Investigative Site

Samsun, Atakum, 55200, Turkey (Türkiye)
Novartis Investigative Site

Izmir, Balcova, 35340, Turkey (Türkiye)
Novartis Investigative Site

Istanbul, Fatih, 34098, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Sihhiye-Altindag, 06230, Turkey (Türkiye)
Novartis Investigative Site

Ankara, Yenimahalle, 06500, Turkey (Türkiye)
Novartis Investigative Site

Kharkiv, 61068, Ukraine
Novartis Investigative Site

West Midlands, Birmingham, B4 6NH, United Kingdom
Novartis Investigative Site

Edinburgh, EH9 1LF, United Kingdom
Novartis Investigative Site

London, NW1 2BU, United Kingdom
Novartis Investigative Site

London, WC1N 3JH, United Kingdom
Robert Wood Johnson Medical School

New Brunswick, New Jersey, 08901, United States
San Jorge Childrens Hospital

Santurce, 00912, Puerto Rico
UAB Childrens Hospital Harbor Center Neurology Dept

Birmingham, Alabama, 35294, United States
UCSF

San Francisco, California, 94115, United States
University of Miami

Miami, Florida, 33136, United States
University of Utah Clinical Trials Office

Salt Lake City, Utah, 84108, United States
Wayne State University

Detroit, Michigan, 48201, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS